GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00434278
- Locations
- 🇺🇸
Ventura County Medical Ctr, Ventura, California, United States
🇺🇸Pulm & Critical Care Assoc, Jacksonville, Florida, United States
🇺🇸Morristown Memorial Hospital, Morristown, New Jersey, United States
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
Phase 2
Terminated
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2009-12-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00434356
A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT00434252
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
Phase 2
Terminated
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00434226
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
Phase 3
Completed
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT00434642
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
Phase 3
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1015
- Registration Number
- NCT00406419
- Locations
- 🇺🇸
Trial Information Support Line, South San Francisco, California, United States
A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
Phase 2
Completed
- Conditions
- Allergic Asthma
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2008-01-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00406965
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
Phase 3
Withdrawn
- Conditions
- Lupus Nephritis
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00404157
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
Phase 2
Completed
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00403403
A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1899
- Registration Number
- NCT00401596
© Copyright 2025. All Rights Reserved by MedPath